Trial intelligence / Profile preview

Phase 3b continuation study of PEGylated rFVIII (BAX855) in severe hemophilia A

2013-002236-24Phase 3Completed

Sponsor: Baxter International Inc.
Start: Sep 2013
Modality: Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Countries: 1

Overview

Phase 3, open-label, single-arm trial of rurioctocog alfa pegol in hemophilia A, sponsored by Baxter International Inc. Primary endpoints: Development of inhibitory antibodies to FVIII and Annualized bleeding rate (ABR). Started Sep 2013; status: completed.

Drugs

rurioctocog alfa pegol

Conditions

hemophilia A

Beyond the preview

Go deeper on 2013-002236-24.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-002236-24.